ID Biomedical finalise deal with Tm Technologies:
This article was originally published in Clinica
ID Biomedical and Tm Technologies have dismissed all litigation claims the Canadian companies had against each other. Under the terms of the agreement, Tm has issued to IDB 1,330,000 common shares of Tm stock (see Clinica No 647, p 16).
You may also be interested in...
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.